The Translational Biology of Remyelination: Past, Present, and Future

Robin J. M. Franklin1 and Vittorio Gallo2

Amongst neurological diseases, multiple sclerosis (MS) presents an attractive target for regenerative medicine. This is because the primary pathology, the loss of myelin-forming oligodendrocytes, can be followed by a spontaneous and efficient regenerative process called remyelination. While cell transplantation approaches have been explored as a means of replacing lost oligodendrocytes, more recently therapeutic approaches that target the endogenous regenerative process have been favored. This is in large part due to our increasing understanding of (1) the cell types within the adult brain that are able to generate new oligodendrocytes, (2) the mechanisms and pathways by which this achieved, and (3) an emerging awareness of the reasons why remyelination efficiency eventually fails. Here we review some of these advances and also highlight areas where questions remain to be answered in both the biology and translational potential of this important regenerative process.

Key words: progenitor, remyelination, multiple sclerosis

Introduction

Demyelination, the loss of myelin from an otherwise intact axon, is an unusual pathological event in the CNS is that it often followed by remyelination, a spontaneous regenerative process involving the generation of new oligodendrocytes and the formation of new myelin sheaths (Franklin and ffrench-Constant, 2008; Gallo and Armstrong, 2008). With the restoration of myelin comes the return of myelin functions lost during demyelination, namely, salutatory conduction, the maintenance of axonal integrity and the recovery from functional deficits (Duncan et al., 2009; Franklin et al., 2012). Primary demyelination is a feature of several neurological conditions. In those where demyelination features as a single acute event, such as in traumatic injury, the likelihood is that these lesions will, eventually, undergo spontaneous repair (e.g., Lasiene et al., 2008). However, the situation is somewhat different in the most prevalent demyelinating disease of the adult central nervous system (CNS), multiple sclerosis (MS). MS is a chronic demyelinating disease, often of many decades duration, in which autoimmune-mediated damage to myelin (and in the acute inflammatory phase, to axons) continues to occur episodically. Like all regenerative processes, the efficiency of remyelination declines progressively throughout adulthood (Goldschmidt et al., 2009): the basis of this decline is discussed later in this review. The effects of aging on remyelination are likely to have a profound bearing on the natural history of the disease even though the rate at which remyelination occurs in humans is difficult to assess. The observation that extensive remyelination can be found in older individuals with MS (Patrikios et al., 2006) can not be taken as evidence that remyelination is unaffected by aging (which would make remyelination unique amongst regenerative processes), since in this study there was no way of knowing when a particular lesion occurred or how long it took to remyelinate. The consequence of failing remyelination is that axons remain chronically demyelinated and vulnerable to the irreversible degeneration that underpins the currently untreatable secondary progressive phase of MS. By implication, reversing the declining efficiency of remyelination by its therapeutic enhancement is likely to prove an effective means of addressing the unmet clinical need of providing neuroprotection in the secondary progressive MS (Franklin et al., 2012). Although remyelination enhancement could theoretically be achieved by transplantation of myelinogenic cells (despite the
many practical hurdles of cell identity and source, delivery, and histocompatibility), current evidence suggest that this will not be necessary since the proof-of-principle studies in mice indicate that the effects of aging on the spontaneous regenerative process are reversible and that strategies targeting the endogenous remyelination will prove effective throughout the disease duration (Huang et al., 2011; Ruckl et al., 2012). While cell transplantation remains (and is likely to remain) the approach of choice for the demyelinating conditions of genetic origin (Goldman et al., 2012; Gupta et al., 2012), where the oligodendrocyte lineage is inherently defective, promotion of endogenous remyelination is the current favored strategy for remyelination in MS and will therefore form the focus of this review.

**Endogenous Adult Progenitor Cells with the Potential to Remyelinate**

Substantial OL death occurs in MS and demyelinating disorders (Barnett and Prineas, 2004; Cannella et al., 2007), and in all animal models of demyelination (Aguirre et al., 2007; Mason et al., 2004; Mi et al., 2011; Woodruff and Franklin, 1999; Zhou et al., 2012). Induction of apoptosis in OLs by lentivirus-mediated caspase 9 expression under the MBP promoter results in rapid focal demyelination (Caprariello et al., 2012), demonstrating that demyelination is initiated by OL death itself. Oligodendrocytes (OLs) and Schwann cells are the only cells in the central nervous system that are able to repair demyelinated axons. Schwann cell remyelination of the CNS, which has been reported in MS, spinal cord injury and various experimental models (Itoyama et al., 1983; Zawadzka et al., 2011), occurs under particular circumstances such as when demyelination is associated with astrocyte loss. Here, we will focus on oligodendrocyte remyelination. Although cellular interactions between OLs and other cell types of the CNS regulate the complex process of remyelination, OLs themselves are ultimately responsible for myelin repair. Therefore, recognizing and understanding the intrinsic OL potential to remyelinate under different pathological conditions, and the cellular and molecular signals that regulate this process are crucially important to design future therapies aimed at promoting remyelination.

It is well established that remyelination primarily occurs from endogenous neural progenitor cells (NPCs) and OPCs surviving demyelinating insults and generating new, mature OLs. Analysis of the spatio-temporal dynamics of cellular recovery in demyelinated lesions demonstrated that cells with an OPC phenotype first appear before new myelinating oligodendrocytes are generated (Aguirre et al., 2007; Fancy et al., 2004; Levine and Reynolds, 1999; Watanabe et al., 2002). Genetic fate-mapping studies using a variety of reporter proteins expressed under the control of OPC gene promoters directly demonstrated enhanced oligodendrogenesis from OPCs after demyelination (Aguirre et al., 2007; Zawadzka et al., 2010; Guo et al., 2011; Nakatani et al., 2013). Importantly, this pool of OPCs is renewable between demyelinating episodes (Penderis et al., 2003). A more recent study used a retroviral reporter system to selectively, genetically and permanently label endogenous dividing NG2-expressing progenitors after spinal cord injury confirmed that this cell population is actively involved in myelin repair (Powers et al., 2013). These findings are consistent with reports demonstrating that grafted rodent and human glial progenitors, as well as iPSC-derived OPCs, can extensively repopulate and remyelinate demyelinated areas (Groves et al., 1993; Najim et al., 2013; Windrem et al., 2004). These findings indicate that endogenous adult OPCs and NPCs represent the major cellular targets to promote remyelination in the CNS.

A therapeutic approach of exploiting endogenous progenitor cells for remyelination therefore calls for clearer understanding of many intrinsic properties of adult OPCs, namely: (1) What are the characteristic features of activated, remyelinating OPCs? (2) What is their potential to migrate to different brain regions to repopulate demyelinated areas? (3) How efficient are these progenitor populations in expanding to regenerate the necessary OL numbers, and how effectively do they differentiate into mature, myelinating OLs? (4) Which and where are the major NPC/OPC populations capable of regenerating oligodendrocytes and myelin after demyelination? (5) Are there injury-induced OPCs derived from other cell lineages? These issues have been studied for many years, and some significant progress has recently been made to further uncover the molecular and developmental properties of these progenitors, and identify specific cellular phenotypes and their regenerative potential.

The endogenous population of adult OPCs is characterized by expression of the PDGFRα (Kang et al., 2010; Zhu et al., 2008). NG2 is highly responsive to injury (e.g., Rhodes et al., 2006), and recently its role during remyelination was demonstrated, not only in OPC proliferation, but also as a component of demyelination-induced inflammatory damage (Kucharova et al., 2011). Fate mapping studies and use of different transgenic mouse strains demonstrated that these cells are capable of efficiently regenerating myelinating OLs after demyelination (Aguirre et al., 2007; Zawadzka et al., 2010). Like perinatal OPCs, adult OPCs express the transcription factors Olig1/2 (Aguirre et al., 2007; Cassiani-Ingioni et al., 2006; Fancy et al., 2004; Ligon et al., 2006; Lu et al., 2002; Sim et al., 2002; Zhou et al., 2001), Ascl1 (Nakatani et al., 2013; Parras et al., 2004) and Nkx2.2 (Fancy et al., 2004; Soula et al., 2001; Zhou et al., 2001) under physiological and pathological conditions. Importantly,
expression of the marker proteins that characterize OPCs in the normal and pathological rodent brain has also been revealed in MS tissue (Arnett et al., 2004; Chang et al., 2002; Nait-Oumesmar et al., 2007). The identification and characterization of OPCs in the pathological brain raises the important question of whether there is indeed a phenotype corresponding to an “activated” OPC (Fig. 1).

Both BrdU pulse-chase and fate mapping studies demonstrated that dividing OPCs expressing proliferation markers are actively involved in remyelination (Aguirre et al., 2007; Carroll et al., 1998; Gensert et al., 1997). Intrinsic regulators of OPC proliferation also play an important role in remyelination. In response to CNS demyelination, loss of Cdk2 alters OPC renewal, cell cycle exit, and differentiation (Caillava et al., 2011). Furthermore, Cdk2 deletion accelerates remyelination of demyelinated CNS axons from parenchymal OPCs (Caillava et al., 2011). Interestingly, Cdk4, not Cdk2, may play a crucial role in PNS remyelination after nerve injury (Atanasoski et al., 2008), indicating that different molecular mechanisms regulate OPC and Schwann cell precursor expansion and recruitment during CNS versus PNS remyelination. Finally, developmental regulation of cell cycle activity (Belachew et al., 2002), together with impaired recruitment and differentiation (Shen et al., 2008; Sim et al., 2002), likely underlies the reduction in the OPC regenerative potential observed in adult compared with the developing brain (Sim et al., 2002).

Other cellular features, besides proliferation markers, appear to be typical of “activated” OPCs. Fibroblast growth factor receptor 1 (FGFR1) expression is upregulated in OPCs after cuprizone-induced demyelination and its deletion during chronic demyelination reduces the number of OPCs, but promotes their differentiation to oligodendrocytes (Zhou et al., 2012). Both Shh and a member of the SoxF transcription factor family, Sox 17, are expressed at high levels in OPCs after demyelination, but are either undetectable or expressed at much lower levels in OPCs under normal physiological conditions (Ferent et al., 2013; Ming et al., 2013; Moll et al., 2013). Shh and Sox17 have both been identified as positive regulators of oligodendrogenesis and remyelination (Ferent et al., 2013; Ming et al., 2013), and Shh transcripts are detected only in OPCs engaged in remyelination (Ferent et al., 2013). Musashi1 (Msi1), Myt1, Tcf4 (Tcf7l2) and Nkx2.2 are expressed in OPCs in white matter regions during development, and their expression is upregulated in OPCs after demyelination (Dobson et al., 2008; Fancy et al., 2004, 2009; Sim et al., 2002; Vana et al., 2007; Watanabe et al., 2004). Furthermore, although Olig2-expressing progenitors appear to be a major cell population involved in remyelination (Aguirre et al., 2007; Fancy et al., 2004; Menn et al., 2004), maintenance of nuclear Olig2 expression is required for oligodendrocyte regeneration, as translocation of Olig2 from the nucleus to the cytoplasm is associated with induction of GFAP expression and astrogliogenesis (Cassiani-Ingoni et al., 2006). Finally, Olig1, which relocates to the nucleus in “activated” OPCs, and Ascl1/Mash1 are also required for remyelination (Arnett et al., 2004; Nakatani et al., 2013). Loss of Olig1 in transplanted NPCs results in astrocyte generation, rather than oligodendrocytes (Whitman et al., 2012), and selective deletion of Ascl1/Mash1 in OPCs prevents remyelination (Nakatani et al., 2013). In conclusion, it appears that expression of proliferation markers, as well as high levels of FGFR1, Shh, Sox17, Msi1, Myt1, Nkx2.2, Tcf4, and Ascl1/Mash1, together with nuclear Olig1/2 expression, may characterize “activated” OPCs engaged in the remyelination process.

Aging strongly affects the potential of endogenous OPCs to remyelinate (Hampton et al., 2012; Ruckh et al., 2012; Sim et al., 2002) and epigenetic mechanisms modulating OPC differentiation program are also regulated by age (Shen et al., 2008). Histone deacetylases (HDACs) are involved in downregulation of inhibitors of oligodendrocyte differentiation during development (Marin-Flusstege et al., 2002; Ye et al., 2009). The efficiency of this process is affected by aging, and remyelination is impaired by in vivo administration of HDAC inhibitors acting on OPCs (Shen et al., 2002).
et al., 2008). Therefore, it appears that HDACs play an important role in remyelination efficiency and their activity is required to suppress inhibitors of OPC differentiation. In addition to HDACs, Na\(^+\)-dependent deacetylases also play a role in oligodendrocyte regeneration and remyelination efficiency. A recent study demonstrated that the nuclear sirtuin SIRT1 acts as an inhibitor of remyelination, because inactivation of this protein leads to expansion of the OPC pool, enhanced remyelination and delayed paralysis in animal models of demyelination (Rafalski et al., 2013). In summary, epigenetic reactivation of developmental mechanisms in OPCs is likely to be an essential component of oligodendrogenesis and remyelination. It will have to be established whether activation of epigenetic mechanisms in distinct pools of OPCs determines recruitment of subpopulations of these cells during myelin regeneration processes of the adult brain.

Two major sources of OPCs are present in the adult brain: the subventricular zone (SVZ) and the parenchyma, which includes the white matter itself (Aguirre et al., 2004, 2007; Levison and Goldman, 1993; Menn et al., 2006; Nait-Oumesmar et al., 1999). The SVZ progenitors involved in remyelination of white matter regions express NG2 and Olig2, as well as markers of Type-C cells, including EGFR (Aguirre et al., 2004, 2007; Menn et al., 2006; Nait-Oumesmar et al., 1999). Differently from Type-B cells, SVZ OPCs actively divide and their proliferation rate is enhanced after demyelination of the corpus callosum (Aguirre et al., 2007; Menn et al., 2006; Nait-Oumesmar et al., 1999). Both parenchymal and SVZ progenitor pools participate in remyelination, although their relative contributions to oligodendrocyte regeneration and remyelination of demyelinated lesions has not yet been quantitatively determined. Furthermore, although many of the molecular pathways involved in proliferation, migration and differentiation of SVZ and parenchymal OPCs after demyelination have been identified, it is still unclear whether these distinct pools of endogenous progenitors are functionally distinct and whether intrinsic molecular mechanisms distinguish their proliferative responses to demyelination. Future studies should be aimed at revealing these differences, by, for example, selectively inhibiting recruitment of either SVZ or parenchymal OPCs in order to measure their relative involvement in remyelination.

A question of great interest in oligodendrocyte regeneration and remyelination is whether specific neural cell lineages display plasticity in postnatal and adult brain under pathological conditions, i.e., can neuronal or glial progenitors “committed to” either a neuronal or an astrocytic fate become diverted to generate different progenies? The potential for instructing immature neurons to generate glia would enable larger pools of endogenous neural progenitors to be targeted and avoid some of the problems associated with heterologous transplantation as a therapeutic approach, such as rejection of heterologous cells, and efficiency and invasiveness of the grafting process. Studies have described changes in cell fate potential after genetic manipulation of specific neuronal progenitor cell populations under normal physiological conditions and in culture. For example, adult hippocampal NPCs change their fate from neurons to OPCs and oligodendrocytes after retroviral-mediated overexpression of bHLH transcription factor Ascl1 (Mash1) (Jessberger et al., 2008). This process is regulated by cell-autonomous and niche-dependent mechanisms (Jessberger and Gage, 2009). Cell lineage plasticity also occurs in GAD65- and Dcx-expressing neuroblasts of the adult SVZ, which generate oligodendrocytes in corpus callosum after focal demyelination (Jablonska et al., 2010). This process occurs together with induced expression of Mash1 and Olig2 in these progenitors, strongly suggesting that bHLH transcription factors act coordinately as essential regulators of oligodendrogenesis from GAD65- and Dcx-expressing neuroblasts. The BMP antagonist chordin was identified as a SVZ signal that promotes oligodendrogenesis from these progenitors, indicating that niche-dependent mechanisms also regulate lineage plasticity of neuroblasts in the SVZ (Jablonska et al., 2010).

One can propose that cell fate plasticity is a major factor supporting endogenous brain repair. Glial progenitor cell lineage plasticity is not entirely surprising, since hippocampal and SVZ astroglial stem cells display multipotency both in vitro and after grafting in vivo (Doetsch et al., 1999; Eriksson et al., 2003; Ganat et al., 2006; Laywell et al., 2000; Yagansawa et al., 2005), however the host environment is critical in determining their survival and differentiation. Various growth factors, neurotrophins, cytokines, and proinflammatory molecules are present in the cellular environment of a demyelinated lesion, where it is likely that they promote or restrict cell fate plasticity in activated neuronal or glial progenitors during regeneration. Therefore, a major aim of future studies will be defining endogenous signaling pathways activated under pathological conditions, and demonstrating their effects on neural progenitor cell plasticity.

The experimental literature discussed above points to a major role of endogenous NG2/PGDFRα-expressing progenitors in remyelination. These cells represent an important target to promote myelin repair, as they have the potential to generate both oligodendrocytes and Schwann cells under pathological conditions (Zawadzka et al., 2010). However, there are still major issues that will have to be resolved and that directly affect the outcome of endogenous OPC-mediated remyelination. It is still undefined to what extent OPC/NPC death occurs in MS lesions (Cui et al., 2013), with subsequent reduction of the endogenous pools of these cells. This is an important and unresolved question, as the
size of this pool directly impacts the efficiency of the repair process (see Franklin and ffrench-Constant, 2008 for review). Furthermore, the influence of the pathological cellular environment, in particular inflammation, can influence the response of NG2 cells to demyelination (Rhodes et al., 2006). These factors will have to be carefully taken into account in designing future strategies aimed at promoting OPC-mediated oligodendrocyte regeneration and remyelination.

**Functional Role of Neurons in Remyelination**

Death of oligodendrocytes and loss of myelin represents a major component of the degenerative processes associated with myelin pathology and demyelination. However, it has become clear that neuronal loss and axonal damage and degeneration also play a crucial role in myelin diseases, including MS (Ganter et al., 1999; Trapp et al., 1998). Evidence obtained in animal models of demyelination, as well as in human MS tissue, supports the idea that compromised axonal function and neuronal loss both cause long-term impairment observed in the chronic progressive phase of MS (Dubois-Dalcq et al., 2005). Therefore, MS and other demyelinating diseases are now regarded as a combination of inflammatory damage to oligodendrocytes and neurodegeneration.

Similar to the process that occurs during development, repair of a demyelinated lesion depends on appropriate matching between oligodendrocytes and axons, i.e. on a coordinated regenerative process that involves both glia and neurons. The number of oligodendrocytes necessary to repair a lesion will ultimately depend on the size of the lesion, in particular the number of demyelinated axons and the length of demyelinated segments. However, the cellular and molecular mechanisms that regulate appropriate myelin thickness and intermodal length during remyelination are still unknown. Are the same axonal signals that act on oligodendrocytes to modulate developmental myelination also effective during remyelination, and what types of communication occur between axons and oligodendrocytes during this process? Some of these crucial cellular interactions have been identified, including electrical activity-mediated communication, release of soluble factors and cell-to-cell contact, and are still being actively investigated.

Electrical activity and proper axonal function are required for developmental myelination (Demerens et al., 1996; Wake et al., 2011). In fact, it is likely that synchronization between oligodendrocyte developmental programs and specific patterns of axonal activity is crucial for timing of oligodendrocyte differentiation and initiation of myelination. Furthermore, imaging studies have demonstrated that neuronal activity and learning cause structural changes in white matter regions of the brain; although the underlying cellular and molecular events are still largely unknown (see Zatorre et al., 2012 for review). Recent behavioral studies identified a critical developmental period for social experience-dependent oligodendrocyte maturation and myelination (Makinodan et al., 2012), as well as impaired myelination in the adult brain caused by social isolation (Liu et al., 2012). These studies strongly suggest that experience-dependent neuronal activity results in white matter plasticity both in the developing and adult brain.

Earlier studies in the CNS demonstrated that blockage of action potentials in axons results in defective myelination, whereas increase in electrical activity enhances myelination (Demerens et al., 1996). The mechanisms by which electrical activity in axons influence myelination are still incompletely defined, although axonal signals, e.g., glutamate and adenosine, that are released by specific patterns of electrical stimulation in axons and regulate myelination have been identified (Stevens et al., 2002; Wake et al., 2011). Adenosine is thought to act on purinergic receptors expressed by OPCs (Stevens et al., 2002), whereas glutamate is believed to act on receptors of the AMPA, kainate and NMDA subtype (Gallo et al., 1996; Kárádóttir et al., 2005; Kukley et al., 2007; Patneau et al., 1994; Ziskin et al., 2007). Importantly, astrocytes are also involved in activity-dependent regulation of myelination and cooperate with other neural cell types to modulate this process. ATP released by axons through specific patterns of stimulation induces release of cytokine leukemia inhibitory factor (LIF) by astrocytes, which in turn promotes myelination (Ishibashi et al., 2006). More recently, electrical activity was found to promote myelination in a frequency-dependent fashion, and neuronal cAMP was identified as a major mediator of this effect (Malone et al., 2013). However, direct evidence that electrical activity per se modulates remyelination in the CNS in vivo is still lacking.

Compromised axonal function is likely to further reduce remyelination potential, as distribution of metabolites, organization of ionic channels and patterns of electrical activity are permanently altered (see Franklin and ffrench-Constant, 2008, for review). Therefore, it is important to understand how demyelination impacts functional organization of axons and ultimately their physiological properties. First, mitochondrial functions are severely affected in degenerating axons (Dutta et al., 2006), as axonal ATP is depleted and Na+/K+ ATPase failure occurs as a consequence of inflammation (Smith, 2007). This causes a reduced ability of axons to prevent pathological Na+ influx and to extrude Na+ ions. Higher intracellular Na+ concentrations in axons trigger a cascade of events, including enhanced Na+-Ca2+ exchange channel activity, increased Ca2+ influx, activation of proteases, and disruption of neurofilament integrity and axonal transport (Dutta et al., 2006; Stys et al., 1992). Consistent with this hypothesis, in MS tissue and
animal models, the number of mitochondria in axons significantly changes as a result of demyelination and during remyelination, as demonstrated by immunolabeling with antibodies against porin, a voltage-gated anion channel selectively expressed in the mitochondrial membrane (Zambonin et al., 2011). In particular, mitochondrial content significantly increases in chronically or acutely demyelinated axons, and decreases during remyelination, although the overall number of mitochondria in remyelinated axons is still higher than in myelinated axons (Zambonin et al., 2011). These results indicate that demyelinated axons display a large increase in energy demand, which is partially attenuated by remyelination.

Myelin plays an essential role in organization of axonal domains, because the organization of nodal, paranodal, and juxtaparanodal proteins, including ion channels, is severely compromised in demyelinated axons (see Waxman, 2006 for a review). In demyelinated axons, voltage-gated Na⁺ channel (NaV) expression and nodal distribution are significantly altered—in particular the small conductance channel NaV 1.2 is upregulated and more evenly redistributed on the intermodal axolemma (Craner et al., 2003). Furthermore, the larger conductance NaV 1.6 channels, which are normally segregated at the nodes of Ranvier after myelination, are also more evenly distributed on axons (Craner et al., 2004). Similar neuronal abnormalities were also detected in MS tissue (Craner et al., 2004). Therefore, it is likely that a large upregulation of Na⁺ conductance will cause a drastic increase in intra-axonal Na⁺ ions, with subsequent protease activation and axonal loss.

Expression and distribution of paranodal (paranodin/Caspr) and juxtaparanodal (Kv channels and Caspr) proteins is also altered in demyelinated axons found in MS tissue, as they are all diffusely distributed, rather than clustered in specific domains (Coman et al., 2006). Conversely, in remyelinated lesions (shadow plaques and partially remyelinated plaques), aggregates of nodal and perinodal constituents were detected (Coman et al., 2006), further indicating that myelin contributes to maintaining normal distribution of axonal proteins. Thus, demyelination causes major changes in fundamental structural and physiological properties of axons, which prevent normal saltatory conduction and disrupt normal axo-glial interactions. These abnormalities of intrinsic axonal properties contribute to inhibition of myelin repair, which in turn further compromises axonal viability leading to degeneration.

A different type of axonal-oligodendroglial communication has been recently characterized, based on the pioneering work of Bergles and colleagues demonstrating the presence of synapses on NG2-expressing OPCs (Bergles et al., 2000). Although these neuron-NG2 cell synapses were originally identified in gray matter, they are also found in NG2 cells present in white matter, both under normal physiological conditions (Kukley et al., 2007; Ziskin et al., 2007) and after demyelination (Exteberria et al., 2010). Axon collaterals in corpus callosum make direct synaptic contacts with OPCs, which receive both glutamatergic and GABAergic synapses (Lin and Bergles, 2003). At early postnatal developmental stages both neurotransmitter amino acids depolarize the NG2 cell membrane. Recent evidence indicates that glutamate regulates NG2 cell proliferation and differentiation in vivo (Mangin et al., 2012), as previously observed in OPCs in different culture systems (Gallo et al., 1996; Yuan et al., 1998). The direct demonstration of synapses being present on actively dividing NG2 cells (Ge et al., 2009; Kukley et al., 2008) is consistent with a developmental function, in particular on cell proliferation. Furthermore, downregulation of neuron-NG2 cell synapses occurs as OPCs mature to premyelinating and myelinating OLs (De Biase et al., 2010), indicating a specific role for these synapses at earlier developmental stages that precede myelination (Gallo et al., 2008).

Synaptic communication between neurons and OPCs is likely to regulate not only OPC development, but also oligodendrocyte regeneration and remyelination. NG2 cells in the SVZ do not display synaptic contacts with neurons; however, they receive glutamatergic synaptic inputs from axonal collaterals once they migrate from the SVZ into the corpus callosum within a few days after toxin-induced focal demyelination (Exteberria et al., 2010). Similar to the process that occurs during development, these synaptic inputs are also downregulated at more mature stages during remyelination (Exteberria et al., 2010). Therefore, axons still establish and maintain contacts with NG2 cells during early phases of remyelination, suggesting that glutamate-induced depolarization contributes to NG2 cell cycle exit and initiation of differentiation also under pathological conditions.

In addition to soluble factors and neurotransmitters, membrane-bound molecules present in axons regulate myelination, and likely remyelination. The immunoglobulin superfamily member's neural cell adhesion molecules (NCAMs) have been implicated in cell-cell adhesion and migration, and their expression is developmentally regulated, indicating specific roles during critical phases of CNS maturation (Coman et al., 2005). PSA-NCAM expression in axons is drastically downregulated during myelination and its loss from the axonal surface coincides with initiation of myelination (Charles et al., 2000). This suggests that PSA-NCAM is an inhibitor of myelination, and downregulation of this adhesion molecule is a necessary step to convert axons to a myelination permissive state. Studies in postmortem MS tissue are consistent with this hypothesis. In fact, PSA-NCAM is normally absent from the adult brain, but is re-expressed on demyelinated axons present in MS plaques, and not in shadow plaques.
strongly suggesting that it might be one of the endogenous inhibitors of remyelination in MS (Charles et al., 2002).

Semaphorins are known as developmental signals for both neurons and glia in the CNS (Armendariz et al., 2012; Pasterkamp, 2012). Semaphorins have emerged as important regulators of both OPC migration and differentiation following demyelination. Developmental studies first identified semaphorins 3A and 3F as repulsive and attractive guidance cues for OPCs, respectively. It has subsequently been shown that adult OPCs express class 3 semaphorin receptors, neuropilins and plexins and that neuropilin expression by OPCs increases after demyelination. Gain and loss of function experiments have shown that semaphorin 3A impairs OPC recruitment to the demyelinated area, while semaphorin 3F overexpression accelerates not only OPC recruitment, but also remyelination rate (Platon et al., 2011). Semaphorin 3A, which is expressed at high levels in active MS lesions (Syed et al., 2011), also reversibly inhibits OPC differentiation in culture and prevents remyelination when infused in demyelinated lesions of the CNS (Syed et al., 2011), indicating that this protein might contribute to maintaining OPCs in an undifferentiated state and limit their maturation under pathological conditions.

**Axonal Protection and Remyelination**

Myelin integrity is vital to axonal function and survival, as demonstrated in earlier studies in transgenic mice in which the myelin-specific genes Cnp or Plp were selectively deleted (Griffiths et al., 1998; Lappe-Siefke et al., 2003). In these mouse mutants, myelin sheaths displayed only minor structural abnormalities, but axons progressively degenerated. The absence of PLP protein directly affected axoplasmic transport and further analysis identified the myelin-associated NAD-dependent deacetylase sirtuin 2 as a molecular mediator of this effect (Werner et al., 2007). Studies in human pathological tissues are also consistent with the notion that myelin maintains axonal stability, as demonstrated in Pelizaeus-Merzbacher disease (PMD) and in MS. PMD is caused by PLP gene mutations and causes axon loss (Garbern et al., 2002), indicating that the phenotype observed in animal models reproduces the human disease. In MS tissue, white matter regions in which at least partial remyelination occurred displayed enhanced preservation of axons (Kornek et al., 2000), consistent with findings in animal models demonstrating that remyelination is protective to axons (Irvine and Blakemore, 2008). The cellular and molecular mechanisms causally involved in the effects of myelin on axonal survival are being elucidated, and IGF1, BDNF and GDNF have been identified as candidates for oligodendrocyte-derived trophic factors that promote axonal growth and survival (Smith et al., 2013; Wilkins et al., 2003). An intriguing recent study has revealed activity-dependent axonal release of the neurotransmitter glutamate triggering oligodendroglial secretion of exosomes carrying cargoes of specific proteins and RNA that are taken up by neurons and improve neuronal viability (Frühbeis et al., 2013).

Oligodendrocytes and myelin also play a critical role in metabolic support of axons under normal physiological conditions (Nave, 2010). The role of oligodendrocytes in maintaining long-term axonal integrity has been recognized for a number of years, but only recently have some of the fundamental molecular mechanisms been defined. In particular, both glucose and lactate have been identified as main regulators of oligodendrocyte development and myelination (Rinholm et al., 2011). Furthermore, metabolic coupling between axons and oligodendrocytes has been demonstrated, with oligodendrocytes providing aerobic glycolysis products to axons under conditions that cause energy deprivation (Funfschilling et al., 2012). Finally, a crucial role for the lactate transporter MCT1, which is highly enriched in oligodendrocytes, has been recently revealed, as disruption of MCT1 causes axon damage and neuronal loss (Lee et al., 2012). A role for oligodendroglial MCT1 has also been suggested in the pathogenesis of ALS (Lee et al., 2012).

These recent studies have further elucidated how oligodendrocyte loss and demyelination could impact short- and long-term axonal integrity, and ultimately neuronal survival. Conversely, oligodendrocyte regeneration and prompt remyelination would prevent axons from undergoing a sequence of physiological changes that leads to irreversible damage. Remyelination not only restores normal axonal conduction and physiological patterns of electrical activity, but also protects axons from further inflammatory-induced degeneration (Black et al., 2006).

**Conclusion and Perspectives**

The studies discussed above demonstrate that neurons and oligodendrocytes form a unique, mutually beneficial cellular partnership that can be severely affected by the compromised viability of either cell type. To elucidate the functional role of neurons and their activity on remyelination, future efforts should be focused on developing experimental approaches that will allow simultaneous monitoring of electrical activity in axons and their myelination status in vivo. These approaches should be combined with integrated analysis in animal models and in human brain. Field potential recordings (Crawford et al., 2009) combined with imaging techniques (Zatorre et al., 2012) will allow a more accurate evaluation of action potential propagation along axons and functional integrity of white matter regions.

Diffusion tensor imaging studies and the use of more sophisticated multimodal imaging techniques will help define real-time microstructural changes occurring in white matter during remyelination. In neurons, these changes relate to
axon number and diameter, axon density, axon branching and directionality, and extent of remyelination. In non-neuronal cells, changes in macroglia and microglia number and size, as well as angiogenesis will affect imaging results. A relatively new MR technique, serial magnetization transfer (MT), that appears to be particularly sensitive to detecting myelination (Laule et al., 2007), has been used to evaluate demyelination, axonal loss and nerve degeneration (Horsfield, 2005). Furthermore, MT was also used to investigate natural variation of white matter microstructure and composition in healthy subjects (Kang et al., 2011). This experimental approach is also useful to better determine myelin content and distribution in disease. Finally, positron emission tomography can be used to image vital stains for myelin (Stankoff et al., 2011) and maps of multi-exponential T2 relaxation times can provide myelin measures (Laule et al., 2007).

Acknowledgment
Grant sponsor: NIH; Grant numbers: R01NS045702; R01NS056427; Grant sponsor: National Multiple Sclerosis Society; Grant number: RG 4019; Grant sponsor: UK Multiple Sclerosis Society.

The authors thank Dr. Jonathan Ritter for Fig. 1 and Dr. Li-Jin Chew for discussion.

References

Aguirre AA, Chittajallu R, Belachew S, Gallo V. 2004. NG2-expressing cells in the subventricular zone are type C-like cells and contribute to interneuron generation in the postnatal hippocampus. J Cell Biol 165:575–589.

Aguirre A, Dupree JL, Mangin JM, Gallo V. 2007. A functional role for EGFR signaling in myelination and remyelination. Nat Neurosci 10:990–1000.

Arnedizárrtz BG, Bibrian A, Pérez-Martínez E, Martínez A, de Castro F, Sonano E, Burgaya F. 2012. Expression of Semaphorin 4F in neurons and brain oligodendrocytes and the regulation of oligodendrocyte precursor migration in the optic nerve. Mol Cell Neurosci 49:54–67.

Arnett HA, Fancy SP, Albertas JA, Zhao C, Plant SR, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD. 2004. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111–2115.

Atanassoski S, Boentert M, De Ventura L, Pohl H, Baranek C, Beier K, Young B, Lubetzki C. 1996. Induction of myelination in the central nervous system by electrical activity. Proc Natl Acad Sci USA 93:67–71.

Barnett MH, Prineas JW. 2004. Relapsing and remitting multiple sclerosis: Pathology of the newly forming lesion. Ann Neurol 55:458–468.

Belachew S, Aguirre AA, Wang H, Vautier F, Yuan X, Anderson S, Kirby M, Gallo V. 2002. Cyclin-dependent kinase-2 controls oligodendrocyte progenitor cell cycle progression and is downregulated in adult oligodendrocyte progenitors. J Neurosci 22:8553–8562.

Bergles DE, Roberts JD, Somogy P, Jahr CE. 2000. Glutamate synapses on oligodendrocyte precursor cells. Nature 405:187–191.

Black JA, Liu S, Hains BC, Saab CY, Waxman SG. 2006. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 129:3196–3208.

Cailla C, Vendemboch R, Jablonska B, Debouz C, Spigoni G, Gallo V, Malgrange B, Baron-Van Evercooren A. 2011. Cdk2 loss accelerates precursor differentiation and remyelination in the adult central nervous system. J Cell Biol 193:397–407.

Cannella B, Gaupp S, Omari KM, Raine CS. 2007. Multiple sclerosis: Death receptor expression and oligodendrocyte apoptosis in established lesions. J Neuroimmunol 188:128–137.

Caprariello AV, Mangia S, Miller RH, Selkirk SM. 2012. Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination. Ann Neurol 72:395–405.

Carroll WM, Jennings AR, Ironside LJ. 1998. Identification of the adult resting progenitor cell by autoradiographic tracking of oligodendrocyte precursor cells in experimental CNS demyelination. Brain 121:293–302.

Cassiani-ingoni R, Colosaygan T, Xue H, Reichert-Scrivener SA, Wiendi H, Rao MS, Magnus T. 2006. Cytoplasmic translocation of Olig2 in adult glial progenitors marks the generation of reactive astrocytes following autoimmune inflammation. Exp Neurol 201:349–358.

Chang A, Tourtelotte WW, Rudick R, Trapp BD. 2002. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. New Engl J Med 346:165–173.

Charles P, Fernandez MP, Stankoff B, Aigrot MS, Colin C, Rougon G, Zalc B, Lubetzki C. 2000. Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule. Proc Natl Acad Sci USA 97:7585–7590.

Charles P, Reynolds R, Selhiean D, Rougon G, Aigrot MS, Niezgoda A, Zalc B, Lubetzki C. 2002. Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? Brain 125:1972–1979.

Coman I, Aigrot MS, Selhiean D, Reynolds R, Girault JA, Zalc B, Lubetzki C. 2006. Nodal, paranodal and juxtaparanodal axonal proteins during demyelination and remyelination in multiple sclerosis. Brain 129:3186–3195.

Coman I, Barbin G, Charles P, Zalc B, Lubetzki C. 2005. Axonal signals in central nervous system myelination, demyelination and remyelination. J Neurosci 23:67–71.

Craner MJ, Hains BC, Lo AC, Black JA, Waxman SG. 2004. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127:294–303.

Craner MJ, Lo AC, Black JA, Waxman SG. 2003. Abnormal sodium channel distribution in optic nerve axons in a model of inflammatory demyelination. Brain 126:1552–1561.

Crawford DK, Mangiardi M, Tawani-woodruff SK. 2009. Assaying the functional effects of demyelination and remyelination: Revisiting field potential recordings. J Neurosci Methods 182:25–33.

Cui Qi, Kuhlmann T, Miron VE, Yang J, Gris P, Kennedy TE, Almazan G, Antel J. 2013. Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis. Am J Pathol 183:516–525.

De Biase LM, Nishiyama A, Bergles DE. 2010. Excitability and synaptic communication within the oligodendrocyte lineage. J Neurosci 30:3600–3611.

Demersens C, Stankoff B, Logak M, Anglade P, Allinquant B, Couraud F, Zalc B, Lubetzki C. 1996. Induction of myelination in the adult central nervous system by electrical activity. Proc Natl Acad Sci USA 93:9897–9892.

Dobson NR, Zhou YX, Flint NC, Armstrong RC. 2008. Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival. GLia 56:318–330.

Doetsch F, Caprariello AV, Logak M, Anglade P, Allinquant B, Couraud F, Zalc B, Lubetzki C. 1999. Self-renewal and long-term potential of central nervous system progenitor cell by autoradiographic tracking of oligodendrocyte precursors in the adult brain. Cell 97:703–716.

Dobosz NR, Zhou YX, Flint NC, Armstrong RC. 2008. Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival. GLia 56:318–330.

Doetsch F, Caprariello AV, Logak M, Anglade P, Allinquant B, Couraud F, Zalc B, Lubetzki C. 1996. Induction of myelination in the adult central nervous system by electrical activity. Proc Natl Acad Sci USA 93:9897–9892.

Dobson NR, Zhou YX, Flint NC, Armstrong RC. 2008. Musashi1 RNA-binding protein regulates oligodendrocyte lineage cell differentiation and survival. GLia 56:318–330.

Duncan ID, Brower A, Kondoa Y, Curlee JF Jr., Schultz RD. 2009. Extensive nervous system remyelination in multiple sclerosis. Neuron 48:9–12.

Dusek R, Petzold T, Spyer J, Moller JD. 2003. Olig2 is required for remyelination in multiple sclerosis? Brain 126:1552–1561.

Durand M, Casellas F, Logan B, Brown J, Agbathan T, Kaing S, Raine CS, Rowitch DH, Franklin RJM, Stiles CD. 2004. bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 306:2111–2115.

Dumitrescu P, Buzas T, Donaldson K, Higgs S, Tavendale L, Bird T, Pinckers A, Cooper M, Pettinger G. 2008. Olig2 is required for oligodendrocyte lineage. J Neurosci 23:67–71.

Dumitrescu P, Buzas T, Donaldson K, Higgs S, Tavendale L, Bird T, Pinckers A, Cooper M, Pettinger G. 2008. Olig2 is required for oligodendrocyte lineage. J Neurosci 23:67–71.

Dumitrescu P, Buzas T, Donaldson K, Higgs S, Tavendale L, Bird T, Pinckers A, Cooper M, Pettinger G. 2008. Olig2 is required for oligodendrocyte lineage. J Neurosci 23:67–71.
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478–489.

Eriksson C, Bjorklund A, Vidgren K. 2003. Neuronal differentiation following transplantation of expanded mouse neurosphere cultures derived from different embryonic forebrain regions. Exp Neurol 184:615–635.

Etexeberia A, Mangin JM, Aguierre A, Gallo V. 2010. Adult-born SVZ progenitors receive transient glutamatergic synapses during remyelination of the corpus callosum. Nat Neurosci 13:287–289.

Fancy SJ, Baranzini SE, Zhao C, Irvine KA, Kaing S, Sanai N, Franklin RJM, Rowitch DH. 2009. Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 23:1571–1585.

Fancy SJ, Zhao C, Franklin RJM. 2004. Increased expression of Nkx2.2 and Olig2 identifies reactive oligodendrocyte progenitor cells responding to demyelination in the adult CNS. Mol Cell Neurosci 27:247–254.

Ferent J, Zimmer C, Durbec P, Rust M, Trastoff E. 2013. Sonic Hedgehog signaling is a positive oligodendrocyte regulator during demyelination. J Neurosci 33:1759–1772.

Franklin RJM, ffrench-Constant C. 2008. Remyelination in the CNS: From biology to therapy. Nat Rev Neurosci 9:839–855.

Franklin RJM, ffrench-Constant C, Edgar J, Smith K. 2012. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 8:623–634.

Frühbeis C, Fröhlich D, Kuo WP, Amphpornrat J, Thielmann S, Saab AS, Kirchhoff F, Möbus W, Goebelbs S, Nave KA, Schneider A, Simons M, Klugmann M, Trotter J, Krämer-Albers EM. 2013. Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol 11:e1001604.

Fünschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, Brinkmann BG, Kassmann CM, Tzvetanova ID, Möbus W, Díaz F, Meijer D, Suter U, Hamprecht B, Sereda MW, Moraes CT, Fehling CH, Goebbels S, Nave KA. 2012. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 485:517–521.

Gallo V, Armstrong RC. 2008. Myelin repair strategies: A cellular view. Curr Opin Neurol 21:278–283.

Gallo V, Mangin JM, Kukley M, Dietrich D. 2008. Synapses on NG2-expressing progenitors in the brain: Multiple functions? J Physiol 586:3767–3781.

Gallo V, Zhou JM, McBain C, Wright P, Knutsen PL, Armstrong RC. 1996. Oligodendrocyte progenitor cell proliferation and lineage progression are regulated by glutamate receptor-mediated K+ channel block. J Neurosci 16:2659–2670.

Ganat YM, Silbereis J, Cave C, Ngu H, Anderson GM, Ohkubo Y, Mert LR, Vaccarino FM. 2008. Early postnatal astroglial cells produce multilineage precursors and neural stem cells in vivo. J Neurosci 26:8609–8621.

Ganter P, Prince C, Esiri MM. 1999. Spinal cord axonal loss in multiple sclerosis: A post-mortem study. Neuropathol Appl Neurobiol 25:459–467.

Garber JY, Yool DA, Moore GJ, Wilds IB, Faulk MW, Klugmann M, Nave KA, Sistermans EA, van der Knaap MS, Bird TD, Shy ME, Kamholz JA, Griffiths IR. 2002. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 125:551–561.

Ge WP, Zhou L, Luo Q, Jan LY, Jan YN. 2009. Dividing glial cells maintain differentiated properties including complex morphology and functional synapses. Proc Natl Acad Sci USA 106:328–333.

Gensert JM, Goldman JE. 1997. Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 19:197–203.

Goldman SA, Nedergaard M, Windrem MS. 2012. Glial progenitor cell-based treatment and modeling of neurological disease. Science 338:491–495.

Goldschmidt T, Antel J, Konig FB, Bruck W, Kuhlmann T. 2009. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 72:1914–1921.

Griffiths I, Klugmann M, Anderson T, Yool D, Thomas C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA. 1998. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610–1613.

Groves AK, Barnett SC, Franklin RJM, Crang AJ, Mayer M, Blakemore WF, Noble M. 1993. Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature 362:453–455.

Guo F, Maeda Y, Ma J, Delgado M, Sohn J, Miers L, Ko EM, Bannerman P, Xu J, Wang Y, Zhou C, Takebayashi H, Pleasure D. 2011. Macrogliarial plasticity and the origins of reactive astrogliosis in experimental autoimmune encephalomyelitis. J Neurosci 31:11914–11928.

Gupta N, Henry RG, Strober J, Kang SM, Lim DA, Bucci M, Cazavetai E, Gaetano I, Mandelli ML, Ryan T, Perry R, Farrell J, Jeremy RJ, Uliman M, Huhn SL, Barkovich AJ, Rowitch DH. 2012. Neonatal stem cell engraftment and myelination in the human brain. Sci Transl Med 4:155ra14.

Hampton DW, Innes N, Merkler D, Zhao C, Franklin RJM, Chandran S. 2012. Focal immune-mediated white matter demyelination reveals an age-associated increase in axonal vulnerability and decreased remyelination efficiency. Am J Pathol 180:1897–1905.

Horsfield MA. 2005. Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15:585–675.

Huang JK, Jarjour AA, Nait Oumesmar B, Kerninon C, Williams A, Krezel W, Kagechika H, Bauer J, Zhao C, Baron van Evercooren A, Chambon P, ffrench-Constant C, Franklin RJM. 2011. Retinoid X receptor gamma signaling accelerates CNS remyelination. Nat Neurosci 14:45–53.

Ishibashi T, Dakin SA, Stevens B, Lee PR, Kozlov SV, Stewart CL, Fields RD. 2006. Astrocytes promote myelination in response to electrical impulses. Neuron 49:823–832.

Itoyama Y, Webster HD, Richardson EP Jr, Trapp BD. 1983. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions. Ann Neurol 14:339–346.

Jablonska B, Aguierre A, Raymond M, Szabo G, Kitabatake Y, Sailor KA, Ming GL, Song H, Gallo V. 2010. Chordin-induced lineage plasticity of adult SVZ neuroblasts after demyelination. Nat Neurosci 13:541–550.

Jessberger S, Gage FH. 2009. Fate plasticity of adult hippocampal progenitors: Biological relevance and therapeutic use. Trends Pharmacol Sci 30:61–65.

Jessberger S, Toni N, Clemenson GD Jr, Ray J, Gage FH. 2008. Directed differentiation of hippocampal stem/progenitor cells in the adult brain. Nat Neurosci 11:888–893.

Kang SH, Fukaya M, Yang JK, Rothstein JD, Bergles DE. 2010. NG2+ CNS glial progenitors remain committed to the oligodendrocyte lineage in post-natal life and following neurodegeneration. Neuron 68:668–681.

Kang X, Herron TJ, Woods DL. 2011. Regional variation, hemisphere asymmetries and gender differences in pericortical white matter. Neuroimage 56:2011–2023.

Karádöttir R, Cavelier P, Bergersen LH, Attwell D. 2005. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 438:1162–1166.

Komek B, Storch MK, Weissert R, Wallstroem E, Steffel A, Olsson T, Linnington C, Schmidbauer M, Lassmann H. 2000. Multiple sclerosis and chronic autoimmune encephalomyelitis: A comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267–276.

Kucharova K, Chang Y, Boer A, Yong VW, Stallcup WB. 2011. Reduced inflammation accompanied diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation 13:158.

Kukley M, Capetillo-Zarate E, Dietrich D. 2007. Vesicular glutamate release from axons in white matter. Nat Neurosci 10:311–320.

Kukley M, Kiladze M, Tognatta R, Hans M, Swandulla D, Schramm J, Dietrich D. 2008. Glial cells are born with synapses. FASEB J 8:2957–2969.

Lappe-Siefke C, Goebelbs S, Grovel M, Nicksh E, Lee J, Braun PE, Griffiths IR, Nave KA. 2003. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 33:366–374.
Lasiene J, Shupe L, Pemlmutter S, Homer P. 2008. No evidence for chronic demyelination in spared axons after spinal cord injury in a mouse. J Neurosci 28:3887–3896.

Laule C, Vavasour IM, Kolind SH, Li DK, Trabulseee TL, Moore GR, MacKay AL. 2007. Magnetic resonance imaging of myelin. Neurotherapeutics 4:460–484.

Laywell E, Rakic P, Kukekov VG, Holland EC, Steindler DA. 2000. Identification of a multipotent astrocytic stem cell in the immature and adult mouse brain. Proc Natl Acad Sci USA 97:13883–13888.

Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y, Tsingalia A, Jin L, Zhang PW, Pellerin L, Magistratti PJ, Rothstein JD. 2012. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487:443–448.

Levine JM, Reynolds R. 1999. Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination. Exp Neurol 160:333–347.

Levison SW, Goldman JE. 1993. Both oligodendrocytes and astrocytes develop from progenitors in the subventricular zone of postnatal rat forebrain. Neuron 10:201–212.

Ligon KL, Kesanl S, Kitada M, Sun T, Amett HA, Albertia JA, Anderson DJ, Stiles CD, Rowitch DH. 2006. Development of NG2 neural progenitor cells requires Olig gene function. Proc Natl Acad Sci USA 103:7853–7858.

Lin SC, Bergles DE. 2004. Synaptic signaling between GABAergic interneurons and oligodendrocyte precursor cells in the hippocampus. Nat Neurosci 7:24–32.

Liu J, Dietz K, Delooyht JM, Pedre X, Kelkar D, Kaur J, Vialou V, Lobo MK, Dietz DM, Nestler EJ, Dupree J, Casacca P. 2012. Impaired adult myelination in the prefrontal cortex of socially isolated mice. Nat Neurosci 15:1621–1623.

Lu QR, Sun T, Zhu Z, Ma N, Garcia M, Stiles CD, Rowitch DH. 2002. Common developmental requirement for Olg gene function indicates a motor neuron/oligodendrocyte connection. Cell 109:75–86.

Makinoan M, Rosen KM, Ito S, Corfas G. 2012. A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science 337:1357–1360.

Marglin JM, Li P, Scafidi J, Gallo V. 2012. Experience-dependent regulation of NG2 progenitors in the developing barrel cortex. Nat Neurosci 15:1192–1194.

Marin-Husstege M, Muggirooni M, Liu A, Casacca-Bonnef P. 2002. Histone deacetylase activity is necessary for oligodendrocyte lineage progression. J Neurosci 22:10333–10345.

Mason JL, Toews A, Hostettler JD, Morell P, Suzuki K, Goldman JE, Matsushima GK. 2004. Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions. Am J Pathol 164:1673–1682.

Menn B, Garcia-Verduco JM, Yaschine C, Gonzalez-Perez O, Rowitch D, Alvarez-Buylla A. 2006. Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci 26:7907–7918.

Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W, Huang G, Walus L, Rhodes K, Gong BJ, Miller RH, Pepinsky RB. 2011. Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med 17:816–821.

Ming X, Cheu LJ, Gallo V. 2013. Transgenic over-expression of Sox17 promotes oligodendrocyte development and attenuates demyelination. J Neurosci 33:12528–12542.

Moll NM, Hong E, Faveau M, Naruse M, Keminion C, Tepavcevic V, Kloppstein A, Seilhane D, Cheu L-J, Gallo V, Nait-Oumesmar B. 2013. Sox17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple sclerosis. Glia 61:1659–1672.

Nait-Oumesmar B, Decking L, Lachandelier F, Avelana-Adalid V, Bacheclin C, Baron-Van Evercooren A. 1999. Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination. Eur J Neurosci 11:4357–4366.

Nait-Oumesmar B, Picard-Riera N, Keminion C, Decking L, Seilhane D, Häglinger GU, Hirsch EC, Reynolds R, Baron-Van Evercooren A. 2007. Activation of the subventricular zone in multiple sclerosis: Evidence for early glial progenitors. Proc Natl Acad Sci USA 104:4694–4699.

Naym FJ, Lager AM, Zaremba A, Wyatt K, Caprariello AV, Factor DC, Karl RT, Maeda T, Miller RH, Tesar PJ. 2013. Transcription factor-mediated reprogramming of fibroblasts to expandable, myelinogenic oligodendrocyte progenitor cells. Nat Biotechnol 31:426–433.

Nakatani H, Martin E, Hassan H, Clavairoly A, Maire CL, Viadieu A, Keminion C, Delmasure A, Frah M, Weber M, Nakafuku M, Zalc B, Thomas JL, Guillomet F, Nait-Oumesmar B, Parras C. 2013. Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination. J Neurosci 33:9752–9768.

Nave KA. 2010. Myelination and the trophic support of long axons. Nat Rev Neurosci 11:275–283.

Parras CM, Galli R, Britz O, Soares S, Galichet C, Battiste J, Johnson JE, Nakafuku M, Vescovi A, Guillemot F. 2004. Mash1 specifies neurons and oligodendrocytes in the postnatal brain. EMBO J 23:4495–4505.

Pastorkamp RJ. 2012. Getting neural circuits into shape with semaphorins. Nat Rev Neurosci 13:605–618.

Patneau DK, Wright P, Winters C, Mayer ML, Gallo V. 1994. Glial cells of the oligodendrocyte lineage express both kainate- and AMPA preferring subtypes of glutamate receptor. Neurosci 12:357–371.

Patrikios P, Stadelmann C, Kutschenigg A, Rauschka H, Schmidmayer M, Laursen H, Sörensen PS, Bruck W, Lucchiniets C, Lassmann H. 2006. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 129:3165–3172.

Penderis J, Shields SA, Franklin RJM. 2003. Impaired remyelination and depletion of oligodendroglia progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brain 126:1382–1391.

Piaton G, Aigrot MS, Williams A, Moyon S, Tepavcevic V, Mouktine I, Gras J, Matho KS, Schmitt A, Soellner H, Huber AB, Ravassard P, Lubetzki C. 2011. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. Brain 134:1156–1167.

Powers BE, Sellers DL, Lovellat EA, Cheung W, Aalami SP, Zapertov N, Maris DC, Homer PJ. 2013. Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin. Proc Natl Acad Sci USA 110:4075–4080.

Rafalski VA, Ho PP, Brett JO, Ucar D, Dugas JC, Pollina EA, Chow LM, Ibrahim A, Baker SJ, Barres BA, Steenman L, Brunet A. 2013. Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain. Nat Cell Biol 15:614–624.

Rhodes KE, Ravich G, Fawcett JW. 2006. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neurosci 140:87–100.

Ruckh JM, Zhao JW, Shadrach JL, van Wijngaarden P, Rao TN, Waggers AJ, Franklin RJM. 2012. Rejuvenation of regeneration in the aging central nervous system. Cell Stem Cell 10:96–103.

Shen S, Sandovol J, Swiss VA, Li J, Dupree J, Franklin RJM, Casacca-Bonnef P. 2008. Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 11:1024–1034.

Smith CM, Cooksey E, Duncan ID. 2013. Myelin loss does not lead to axonal degeneration in a long-lived model of chronic demyelination. J Neurosci 33:2718–2727.

Smith KK. 2007. Sodium channels and multiple sclerosis: Roles in symptom production, damage and therapy. Brain Pathol 17:230–242.

Soula C, Danesci N, Kan P, Grub V, Poncet C, Cochard P. 2001. Distinct sites of origin of oligodendrocytes and somatic motoneurons in the chick spinal cord: Oligodendrocytes arise from Nkx2.2 expressing progenitors by a Shh-dependent mechanism. Development 128:1369–1379.

Stankoff B, Freeman L, Aigrot MS, Chardain A, Dollé F, Williams A, Galanaud D, Armand L, Lehericy S, Lubetzki C, Zalc B, Bottlaender M. 2011. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4-methylaminophenyl)-6-hydroxybenzothia-zole. Ann Neuro 69:673–680.
Stevens B, Porta S, Haak LL, Gallo V, Fields RD. 2002. Adenosine: A neuron-glial transmitter promoting myelination in the CNS in response to action potentials. Neuron 36:1–20.

Stys PK, Waxman SG, Ransom BR. 1992. Ionic mechanisms of anoxic injury in mammalian CNS white matter: Role of Na+ channels and Na(+)-Ca2+ exchanger. J Neurosci 12:430–439.

Syed YA, Hand E, Möbius W, Zhao C, Hofer M, Nave KA, Kotter MR. 2011. Inhibition of CNS remyelination by the presence of semaphorin 3A. J Neurosci 31:3719–3728.

Wake H, Lee PR, Fields RD. 2011. Control of local protein synthesis and initial events in myelination by action potentials. Science 333:1647–1651.

Waxman S. 2006. Axonal conduction and injury in multiple sclerosis: The role of sodium channels. Nat Rev Neurosci 7:932–941.

Waxman S, Hadzic T, Nishiyama A. 2004. Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia 46:311–322.

Watanabe M, Toyama Y, Nishiyama A. 2002. Differentiation of proliferated NG2-positive glial progenitor cells in a remyelinating lesion. J Neurosci Res 69:826–836.

Woodruff RH, Franklin RJM. 1999. The expression of myelin protein mRNAs during remyelination of lysolecithin-induced demyelination. Neurobiol Appl Neurobiol 25:226–235.

Zambonin JL, Zhao C, Ohno N, Campbell GR, Engeham S, Zabreva I, Schwarz N, Lee SE, Frischer JM, Turnbull DM, Trapp BD, Lassmann H, Franklin RJM, Mahad DJ. 2011. Increased mitochondrial content in remyelinated axons: Implications for multiple sclerosis. Brain 134:1901–1913.

Zatorre RJ, Fields RD, Johansen-Berg H. 2012. Plasticity in gray and white: Neuroimaging changes in brain structure during learning. Net Neurosci 15:528–536.

Zawadzka M, Rivers LE, Fancy SP, Zhao C, Tripathi R, Jamen F, Young K, Goncharevich A, Pohl H, Rizzi M, Rowitch DH, Kessaris N, Suter U, Richardson WD, Franklin RJM. 2010. CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination. Cell Stem Cell 6:578–590.

Zhou Q, Choi G, Anderson DJ. 2001. The bHLH transcription factor Olig2 promotes oligodendrocyte differentiation in collaboration with Nkx2.2. Neuron 31:791–807.

Zhou YX, Pannu R, Le TQ, Armstrong RC. 2012. Fibroblast growth factor 1 (FGFR1) modulation regulates repair capacity of oligodendrocyte progenitor cells following chronic demyelination. Neurobiol Dis 45:196–205.

Zhu X, Bergles DE, Nishiyama A. 2008. NG2 cells generate both oligodendrocytes and gray matter astrocytes. Development 135:145–157.

Ziskin JL, Nishiyama A, Rubio M, Fukaya M, Bergles D. 2007. Vesicular release of glutamate from unmyelinated axons in white matter. Nat Neurosci 10:321–330.